Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma

Stem Cells and Development

Volumn 22, Issue 13, 2013, Pages 1870-1882

  Yulyana, Yulyana ^a   Endaya, Berwini B ^a,g   Ng, Wai H ^b   Guo, Chang M ^c   Hui, Kam M ^a,d,e,f   Lam, Paula Y P ^a,d,e   Ho, Ivy A W ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBENOXOLONE; CONNEXIN 43; DEATH RECEPTOR 5; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL COMMUNICATION; CELL DEATH; CELL HOMING; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GAP JUNCTION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; UPREGULATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CARBENOXOLONE; CELL LINE, TUMOR; CONNEXIN 43; GAP JUNCTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIMPLEXVIRUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; SIMPLEXVIRUS;

EID: 84879386684     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0529     Document Type: Article

References (57)

1. Lowenstein PR. (2010). Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J Clin Oncol 28:4670-4673.
2. Griffith TS, B Stokes, TA Kucaba, JK Earel, Jr., RL Van-Oosten, EL Brincks and LA Norian. (2009). TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 9:9-19.
3. Bellail AC, L Qi, P Mulligan, V Chhabra and C Hao. (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34-41.
4. Thorburn A, K Behbakht and H Ford. (2008). TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 11:17-24.
5. Lawrence D, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, K Hillan, K Totpal, L DeForge, et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385.
6. Ganten TM, R Koschny, J Sykora, H Schulze-Bergkamen, P Buchler, TL Haas, MB Schader, A Untergasser, W Stremmel and H Walczak. (2006). Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12:2640-2646.
7. Zhang Y and B Zhang. (2008). TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6:1861-1871.
8. Zhang L, H Zhu, F Teraishi, JJ Davis, W Guo, Z Fan and B Fang. (2005). Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7:594-602. (Pubitemid 40967760)
9. Haag C, D Stadel, S Zhou, MG Bachem, P Moller, KM Debatin and S Fulda. (2010). Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptorinduced apoptosis in pancreatic cancer cells. Gut 60:225-237.
10. Hingtgen S, X Ren, E Terwilliger, M Classon, R Weissleder and K Shah. (2008). Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther 7:3575-3585.
11. Soria JC, E Smit, D Khayat, B Besse, X Yang, CP Hsu, D Reese, J Wiezorek and F Blackhall. (2010). Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527-1533.
12. Bagci-Onder T, H Wakimoto, M Anderegg, C Cameron and K Shah. (2010). A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 71:154-163.
13. Naumann I, R Kappler, D von Schweinitz, KM Debatin and S Fulda. (2011). Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 17:3204-3218.
14. Bangert A, S Cristofanon, I Eckhardt, BA Abhari, S Kolodziej, S Hacker, SH Vellanki, J Lausen, KM Debatin and S Fulda. (2012). Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 31:4677-4688.
15. Westhoff MA, S Zhou, MG Bachem, KM Debatin and S Fulda. (2008). Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 27:5169-5181.
16. Willecke K, J Eiberger, J Degen, D Eckardt, A Romualdi, M Guldenagel, U Deutsch and G Sohl. (2002). Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 383:725-737. (Pubitemid 34649891)
17. Sagar GD and DM Larson. (2006). Carbenoxolone inhibits junctional transfer and upregulates Connexin43 expression by a protein kinase A-dependent pathway. J Cell Biochem 98:1543-1551. (Pubitemid 44141858)
18. Oliveira R, C Christov, JS Guillamo, S de Bouard, S Palfi, L Venance, M Tardy and M Peschanski. (2005). Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol 6:7.
19. Drug information online. Drugs.com. (2011). Carbenoxolone. Available fromwww.drugs.com/international/carbenoxolone. html. (Accessed on 18 March, 2013).
20. Davidson JS and IM Baumgarten. (1988). Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships. J Pharmacol Exp Ther 246:1104-1107.
21. Jiang Y, BN Jahagirdar, RL Reinhardt, RE Schwartz, CD Keene, XR Ortiz-Gonzalez, M Reyes, T Lenvik, T Lund, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49. (Pubitemid 34742565)
22. Deak E, E Seifried and R Henschler. (2010). Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol 29:514-529.
23. Ho IA, KY Chan, WH Ng, CM Guo, KM Hui, P Cheang and PY Lam. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27:1366-1375.
24. Mueller LP, J Luetzkendorf, M Widder, K Nerger, H Caysa and T Mueller. (2011). TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 18:229-239.
25. Ho IA, KY Chan, L Miao, WS Shim, CM Guo, P Cheang, KM Hui and PY Lam. (2008). HSV-1 amplicon viral vectormediated gene transfer to human bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 15:553-562.
26. Carlson BL, JL Pokorny, MA Schroeder and JN Sarkaria. (2011). Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol Chapter 14:Unit 14 16.
27. Davidson JS, IM Baumgarten and EH Harley. (1986). Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochem Biophys Res Commun 134:29-36. (Pubitemid 16144018)
28. Wang S. (2008). The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27:6207-6215.
29. Herrero-Gonzalez S, JC Valle-Casuso, R Sanchez-Alvarez, C Giaume, JM Medina and A Tabernero. (2009). Connexin43 is involved in the effect of endothelin-1 on astrocyte proliferation and glucose uptake. Glia 57:222-233.
30. Lampe PD and AF Lau. (2004). The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol 36:1171-1186. (Pubitemid 38515659)
31. Herbst RS, SG Eckhardt, R Kurzrock, S Ebbinghaus, PJ O'Dwyer, MS Gordon, W Novotny, MA Goldwasser, TM Tohnya, et al. (2010). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846.
32. Plotkin LI, SC Manolagas and T Bellido. (2002). Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 277:8648-8657. (Pubitemid 34968331)
33. Mesnil M, S Crespin, JL Avanzo and ML Zaidan-Dagli. (2005). Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 1719:125-145. (Pubitemid 41785641)
34. Cottin S, PV Gould, L Cantin and M Caruso. (2011). Gap junctions in human glioblastomas: implications for suicide gene therapy. Cancer Gene Ther 18:674-681.
35. Cottin S, K Ghani and M Caruso. (2008). Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. Cancer Gene Ther 15:823-831.
36. Boengler K, G Dodoni, A Rodriguez-Sinovas, A Cabestrero, M Ruiz-Meana, P Gres, I Konietzka, C Lopez-Iglesias, D Garcia-Dorado, et al. (2005). Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 67:234-244. (Pubitemid 40943616)
37. Rodriguez-Sinovas A, K Boengler, A Cabestrero, P Gres, M Morente, M Ruiz-Meana, I Konietzka, E Miro, A Totzeck, et al. (2006). Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ Res 99:93-101. (Pubitemid 44297060)
38. Ruiz-Meana M, A Rodriguez-Sinovas, A Cabestrero, K Boengler, G Heusch and D Garcia-Dorado. (2008). Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia-reperfusion injury. Cardiovasc Res 77:325-333. (Pubitemid 351197646)
39. Jensen K, A Patel, J Klubo-Gwiezdzinska, A Bauer and V Vasko. (2011). Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis. Endocr RelatCancer 18:613-626.
40. Sharrow AC, Y Li, A Micsenyi, RD Griswold, A Wells, SS Monga and HC Blair. (2008). Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL. Exp Cell Res 314:297-308. (Pubitemid 350216101)
41. Hao JL, K Suzuki, Y Lu, S Hirano, K Fukuda, N Kumagai, K Kimura and T Nishida. (2005). Inhibition of gap junctionmediated intercellular communication by TNF-alpha in cultured human corneal fibroblasts. Invest Ophthalmol Vis Sci 46:1195-1200. (Pubitemid 41685853)
42. Theiss C, A Mazur, K Meller and HG Mannherz. (2007). Changes in gap junction organization and decreased coupling during induced apoptosis in lens epithelial and NIH-3T3 cells. Exp Cell Res 313:38-52. (Pubitemid 44958452)
43. Zundorf G, S Kahlert and G Reiser. (2007). Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture. J Neurochem 102:508-521. (Pubitemid 47000594)
44. Shenoy K, Y Wu and S Pervaiz. (2009). LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res 69:1941-1950.
45. Yodkeeree S, B Sung, P Limtrakul and BB Aggarwal. (2009). Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 69:6581-6589.
46. Prasad S, J Ravindran, B Sung, MK Pandey and BB Aggarwal. (2010). Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 9:856-868.
47. Olbina G and W Eckhart. (2003). Mutations in the second extracellular region of connexin 43 prevent localization to the plasma membrane, but do not affect its ability to suppress cell growth. Mol Cancer Res 1:690-700. (Pubitemid 36870522)
48. Herrero-Gonzalez S, E Gangoso, C Giaume, CC Naus, JM Medina and A Tabernero. (2010). Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells. Oncogene 29:5712-5723.
49. Giardina SF, M Mikami, F Goubaeva and J Yang. (2007). Connexin 43 confers resistance to hydrogen peroxide-mediated apoptosis. Biochem Biophys Res Commun 362:747-752. (Pubitemid 47368157)
50. Lee HJ, HJ Lee, EJ Sohn, EO Lee, JH Kim, MH Lee and SH Kim. (2012). Inhibition of connexin 26/43 and extracellularregulated kinase protein plays a critical role in melatonin facilitated gap junctional intercellular communication in hydrogen peroxide-treated HaCaT keratinocyte cells. Evid Based Complement Alternat Med 2012:589365.
51. Park EJ, KS Choi, YH Yoo and TK Kwon. (2012). Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs 24:260-269.
52. You RI, YC Chang, PM Chen, WS Wang, TL Hsu, CY Yang, CT Lee and SL Hsieh. (2008). Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 111:1480-1488.
53. Sia KC, WK Chong, IA Ho, Y Yulyana, B Endaya, H Huynh and PY Lam. (2010). Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. J Gene Med 12:848-858.
54. Leshchenko Y, S Likhodii, W Yue, WM Burnham and JL Perez Velazquez. (2006). Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci 7:3.
55. Kelley SK, LA Harris, D Xie, L Deforge, K Totpal, J Bussiere and JA Fox. (2001). Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosisinducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38. (Pubitemid 32905115)
56. Rozanov DV, AY Savinov, VS Golubkov, OL Rozanova, TI Postnova, EA Sergienko, S Vasile, AE Aleshin, MF Rega, M Pellecchia and AY Strongin. (2009). Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther 8:1515-1525.
57. Stupp R, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, RC Janzer, SK Ludwin, A Allgeier, B Fisher, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.